Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe

IMPORTANCE Generalized anxiety disorder (GAD) is poorly understood compared with other anxiety disorders, and debates persist about the seriousness of this disorder. Few data exist on GAD outside a small number of affluent, industrialized nations. No population-based data exist on GAD as it is curre...

Descripción completa

Detalles Bibliográficos
Autores: Ruscio AM, Hallion LS, Lim CC, Aguilar-Gaxiola S, Al-Hamzawi A, Alonso J, Andrade LH, Borges G, Bromet EJ, Bunting B, Caldas de Almeida JM, Demyttenaere K, Florescu S, de Girolamo G, Gureje O, Haro JM, He Y, Hinkov H, Hu C, de Jonge P, Karam EG, Lee S, Lepine JP, Levinson D, Mneimneh Z, Navarro-Mateu F, Posada-Villa J, Slade T, Stein DJ, Torres Y, Uda H, Wojtyniak B, Kessler RC, Chatterji S, Scott KM
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2017
País:España
Institución:Fundació Sant Joan de Déu
Repositorio:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
OAI Identifier:oai:fsjd.fundanetsuite.com:p10993
Acceso en línea:https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10993
Access Level:acceso abierto
id ES_219ded2be291397e304bcc6276e9ceee
oai_identifier_str oai:fsjd.fundanetsuite.com:p10993
network_acronym_str ES
network_name_str España
repository_id_str
spelling Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the GlobeRuscio AMHallion LSLim CCAguilar-Gaxiola SAl-Hamzawi AAlonso JAndrade LHBorges GBromet EJBunting BCaldas de Almeida JMDemyttenaere KFlorescu Sde Girolamo GGureje OHaro JMHe YHinkov HHu Cde Jonge PKaram EGLee SLepine JPLevinson DMneimneh ZNavarro-Mateu FPosada-Villa JSlade TStein DJTorres YUda HWojtyniak BKessler RCChatterji SScott KMIMPORTANCE Generalized anxiety disorder (GAD) is poorly understood compared with other anxiety disorders, and debates persist about the seriousness of this disorder. Few data exist on GAD outside a small number of affluent, industrialized nations. No population-based data exist on GAD as it is currently defined in DSM-5. OBJECTIVE To provide the first epidemiologic data on DSM-5 GAD and explore cross-national differences in its prevalence, course, correlates, and impact. DESIGN, SETTING, AND PARTICIPANTS Data come from the World Health Organization World Mental Health Survey Initiative. Cross-sectional general population surveys were carried out in 26 countries using a consistent research protocol and assessment instrument. A total of 147 261 adults from representative household samples were interviewed face-to-face in the community. The surveys were conducted between 2001 and 2012. Data analysis was performed from July 22, 2015, to December 12, 2016. MAIN OUTCOMES AND MEASURES The Composite International Diagnostic Interview was used to assess GAD along with comorbid disorders, role impairment, and help seeking. RESULTS Respondents were 147 261 adults aged 18 to 99 years. The surveys had a weighted mean response rate of 69.5%. Across surveys, DSM-5 GAD had a combined lifetime prevalence (SE) of 3.7%(0.1%), 12-month prevalence of 1.8%(0.1%), and 30-day prevalence of 0.8%(0). Prevalence estimates varied widely across countries, with lifetime prevalence highest in high-income countries (5.0% [0.1%]), lower in middle-income countries (2.8% [0.1%]), and lowest in low-income countries (1.6%[0.1%]). Generalized anxiety disorder typically begins in adulthood and persists over time, although onset is later and clinical course is more persistent in lower-income countries. Lifetime comorbidity is high (81.9% [0.7%]), particularly with mood (63.0%[0.9%]) and other anxiety (51.7%[0.9%]) disorders. Severe role impairment is common across life domains (50.6%[1.2%]), particularly in high-income countries. Treatment is sought by approximately half of affected individuals (49.2%[1.2%]), especially those with severe role impairment (59.4%[1.8%]) or comorbid disorders (55.8% [1.4%]) and those living in high-income countries (59.0%[1.3%]). CONCLUSIONS AND RELEVANCE The findings of this study show that DSM-5 GAD is more prevalent than DSM-IV GAD and is associated with substantial role impairment. The disorder is especially common and impairing in high-income countries despite a negative association between GAD and socioeconomic status within countries. These results underscore the public health significance of GAD across the globe while uncovering cross-national differences in prevalence, course, and impairment that require further investigation.AMER MEDICAL ASSOC2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10993JAMA PsychiatryISSN: 2168622XISSNe: 21686238reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déuinstname:Fundació Sant Joan de DéuInglésinfo:eu-repo/semantics/openAccessoai:fsjd.fundanetsuite.com:p109932026-05-27T12:37:41Z
dc.title.none.fl_str_mv Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
title Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
spellingShingle Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
Ruscio AM
title_short Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
title_full Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
title_fullStr Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
title_full_unstemmed Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
title_sort Cross-sectional Comparison of the Epidemiology of DSM-5 Generalized Anxiety Disorder Across the Globe
dc.creator.none.fl_str_mv Ruscio AM
Hallion LS
Lim CC
Aguilar-Gaxiola S
Al-Hamzawi A
Alonso J
Andrade LH
Borges G
Bromet EJ
Bunting B
Caldas de Almeida JM
Demyttenaere K
Florescu S
de Girolamo G
Gureje O
Haro JM
He Y
Hinkov H
Hu C
de Jonge P
Karam EG
Lee S
Lepine JP
Levinson D
Mneimneh Z
Navarro-Mateu F
Posada-Villa J
Slade T
Stein DJ
Torres Y
Uda H
Wojtyniak B
Kessler RC
Chatterji S
Scott KM
author Ruscio AM
author_facet Ruscio AM
Hallion LS
Lim CC
Aguilar-Gaxiola S
Al-Hamzawi A
Alonso J
Andrade LH
Borges G
Bromet EJ
Bunting B
Caldas de Almeida JM
Demyttenaere K
Florescu S
de Girolamo G
Gureje O
Haro JM
He Y
Hinkov H
Hu C
de Jonge P
Karam EG
Lee S
Lepine JP
Levinson D
Mneimneh Z
Navarro-Mateu F
Posada-Villa J
Slade T
Stein DJ
Torres Y
Uda H
Wojtyniak B
Kessler RC
Chatterji S
Scott KM
author_role author
author2 Hallion LS
Lim CC
Aguilar-Gaxiola S
Al-Hamzawi A
Alonso J
Andrade LH
Borges G
Bromet EJ
Bunting B
Caldas de Almeida JM
Demyttenaere K
Florescu S
de Girolamo G
Gureje O
Haro JM
He Y
Hinkov H
Hu C
de Jonge P
Karam EG
Lee S
Lepine JP
Levinson D
Mneimneh Z
Navarro-Mateu F
Posada-Villa J
Slade T
Stein DJ
Torres Y
Uda H
Wojtyniak B
Kessler RC
Chatterji S
Scott KM
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
description IMPORTANCE Generalized anxiety disorder (GAD) is poorly understood compared with other anxiety disorders, and debates persist about the seriousness of this disorder. Few data exist on GAD outside a small number of affluent, industrialized nations. No population-based data exist on GAD as it is currently defined in DSM-5. OBJECTIVE To provide the first epidemiologic data on DSM-5 GAD and explore cross-national differences in its prevalence, course, correlates, and impact. DESIGN, SETTING, AND PARTICIPANTS Data come from the World Health Organization World Mental Health Survey Initiative. Cross-sectional general population surveys were carried out in 26 countries using a consistent research protocol and assessment instrument. A total of 147 261 adults from representative household samples were interviewed face-to-face in the community. The surveys were conducted between 2001 and 2012. Data analysis was performed from July 22, 2015, to December 12, 2016. MAIN OUTCOMES AND MEASURES The Composite International Diagnostic Interview was used to assess GAD along with comorbid disorders, role impairment, and help seeking. RESULTS Respondents were 147 261 adults aged 18 to 99 years. The surveys had a weighted mean response rate of 69.5%. Across surveys, DSM-5 GAD had a combined lifetime prevalence (SE) of 3.7%(0.1%), 12-month prevalence of 1.8%(0.1%), and 30-day prevalence of 0.8%(0). Prevalence estimates varied widely across countries, with lifetime prevalence highest in high-income countries (5.0% [0.1%]), lower in middle-income countries (2.8% [0.1%]), and lowest in low-income countries (1.6%[0.1%]). Generalized anxiety disorder typically begins in adulthood and persists over time, although onset is later and clinical course is more persistent in lower-income countries. Lifetime comorbidity is high (81.9% [0.7%]), particularly with mood (63.0%[0.9%]) and other anxiety (51.7%[0.9%]) disorders. Severe role impairment is common across life domains (50.6%[1.2%]), particularly in high-income countries. Treatment is sought by approximately half of affected individuals (49.2%[1.2%]), especially those with severe role impairment (59.4%[1.8%]) or comorbid disorders (55.8% [1.4%]) and those living in high-income countries (59.0%[1.3%]). CONCLUSIONS AND RELEVANCE The findings of this study show that DSM-5 GAD is more prevalent than DSM-IV GAD and is associated with substantial role impairment. The disorder is especially common and impairing in high-income countries despite a negative association between GAD and socioeconomic status within countries. These results underscore the public health significance of GAD across the globe while uncovering cross-national differences in prevalence, course, and impairment that require further investigation.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10993
url https://fsjd.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=10993
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv AMER MEDICAL ASSOC
publisher.none.fl_str_mv AMER MEDICAL ASSOC
dc.source.none.fl_str_mv JAMA Psychiatry
ISSN: 2168622X
ISSNe: 21686238
reponame:r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
instname:Fundació Sant Joan de Déu
instname_str Fundació Sant Joan de Déu
reponame_str r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
collection r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869404525340655616
score 15.811543

Similares en LA Referencia